Pharmaceutical policy reform-balancing affordability with incentives for innovation

New England Journal of Medicine

Volumn 374, Issue 8, 2016, Pages 703-706

  Conti, Rena M ^a   Rosenthal, Meredith B ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG PROGRAM; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MEDICARE; PATIENT ADVOCACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; COST CONTROL; ECONOMICS; FEE; LEGISLATION AND JURISPRUDENCE; MANAGEMENT; UNITED STATES;

COST SAVINGS; DRUG COSTS; HEALTH CARE REFORM; HEALTH POLICY; MEDICARE; POLICY MAKING; PRESCRIPTION FEES; UNITED STATES;

EID: 84959419676     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1515068     Document Type: Review

References (5)

1. Daemmrich A. U.S. healthcare reform and the pharmaceutical industry. Harvard Business School Working paper 12-015 September 14, 2011 (http://www.hbs.edu/faculty/Publication%20Files/12-015.pdf).
2. Frank RG. The ongoing regulation of generic drugs. N Engl J Med 2007; 357: 1993-6.
3. IMS Institute for Healthcare Informatics. Medicine use and shifting costs of healthcare: a review of the use of medicines in the United States in 2013 (https://www.imshealth.com/en/thought-leadership/ims-institute/reports/use-of-medicines-in-the-us-2013).
4. Government Accountability Office. Medicare Part B drugs: action needed to reduce financial incentives to prescribe 340B drugs at participating hospitals (http://www.gao.gov/assets/680/670676.pdf).
5. Department of Health and Human Services, Office of the Inspector General. Least costly alternative policies: impact on prostate cancer drugs covered under Medicare Part B. OEI-12-12-00210. November 2012 (ht t p://oig.h hs.gov/oei/repor ts/o ei-12-12-0 0210.pdf).